- Details
- Christopher Wallis and Zachary Klaassen discuss the JAMA Oncology article titled "Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone." The authors of this study aimed to investigate the differences in outcomes with first-line abiraterone therapy between African American and non-Hispanic White men with mCRPC in...
|
- Details
- Alicia Morgans is joined by Frank Schumacher to discuss the study results assessing the association of functional outcomes by decision-making approaches in men with metastatic prostate cancer. Dr. Schumacher and colleagues assessed the association of shared decision-making vs. physician- or patient-directed decisions and measurement of patient quality of life, including patient-reported functional...
|
- Details
- Charles Ryan is joined by Neil Fleshner to discuss the multi-center, open-label, phase III SPLASH study evaluating the efficacy of 177Lu-PNT2002, a PSMA-based radioligand, for men with progressive metastatic castration-resistant prostate cancer (mCRPC) after androgen receptor axis-targeted (ARAT) therapy which is underway and accruing in many sites around the world. Biographies: Neil Fleshner, MD,...
|
- Details
- Phillip Koo is joined by Joseph Osborne to provide a nuclear radiologist's perspective on the equity in prostate cancer clinical trials. Dr. Osborne focuses his talk on three different aspects of clinical trial equity for prostate cancer: Progress, Evolution, and Goals. He also details the Rad Health Equity Lab, created at Weill Cornell to improve access to radiology and bring awareness to health...
|
- Details
- Alicia Morgans and Silke Gillessen discuss the upcoming Advanced Prostate Cancer Consensus Conference scheduled as a hybrid meeting taking place on April 28 - 30, 2022 in Lugano, Switzerland. Clinical management of prostate cancer will be discussed including locally advanced high-risk prostate cancer, biochemical recurrence in prostate cancer, and metastatic hormone-sensitive patient treatments, w...
|
- Details
- In this discussion between Kara Maxwell and Alicia Morgans, Dr Maxwell highlights the role of TP53 in cancer and understanding the Li-Fraumeni syndrome. Inherited germline TP53 pathogenic and likely pathogenic variants (gTP53) cause autosomal dominant multicancer predisposition including Li-Fraumeni syndrome and the work that Drs. Morgans and Maxwell discuss here sought to determine whether gTP53...
|
- Details
- Alicia Morgans speaks with Kim Chi about the MAGNITUDE trial presented at GU ASCO 2022. The Phase III trial investigates the efficacy of combining niraparib, a PARP inhibitor, with abiraterone and prednisone in treating metastatic castration-resistant prostate cancer (mCRPC). The study focuses on patients with and without homologous recombination repair (HRR) gene alterations. Results reveal that...
|
- Details
- Stuart Bloom, MD, a well-known Twin Cities oncologist, joins Charles Ryan, MD to highlight his work on physician burnout including his theatrical play “How to Avoid Burnout in 73 Minutes”. The play represents Dr. Bloom's path to becoming a physician. Dr. Bloom spent the first 30 years of his life as an actor and comedian, the next 31 as a physician. In this conversation, the pair discuss how he co...
|
- Details
- Diane Newman hosts Leanne Schimke to explore the complexities of metastatic prostate cancer with a focus on the role of genomics and PARP inhibitors. Dr. Schimke delves into how advancements in genomics are providing new avenues for personalized treatment, although the field lags about a decade behind breast cancer research. She highlights the importance of differentiating between indolent and agg...
|
- Details
- In this UroToday discussion Alicia Morgans and Ana Aparicio, discuss androgen indifferent prostate cancer and how to define those patients. The conversation kicks off with a discussion on the challenges of defining androgen indifferent prostate cancer patients. Dr. Aparicio then goes into a discussion on TP53, RB1, and PTEN alterations, and how they fit into her recent studies. Dr. Morgans and Dr....
|
